Screening for prostate cancer: U.S. preventive services task force recommendation statement

Annals of Internal Medicine

Volumn 157, Issue 2, 2012, Pages 120-134

  Moyer, Virginia A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; HUMAN; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; UNITED STATES;

EID: 84863961968     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-157-2-201207170-00459     Document Type: Review

References (63)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al, eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011. Accessed at http://seer.cancer.gov/csr/1975_2008/index.html on 6 October 2011.
2. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215-24. [PMID: 12824459]
3. Miller AB. New data on prostate-cancer mortality after PSA screening [Editorial]. N Engl J Med. 2012;366:1047-8. [PMID: 22417259]
4. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8. [PMID: 19297566]
5. Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:192-9. [PMID: 18678846]
6. Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, Goodwin L, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ. 2012;344: d7894. [PMID: 22232535]
7. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101:1325-9. [PMID: 19720969]
8. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:1117-23. [PMID: 20124165]
9. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:762-71. [PMID: 21984740]
10. Chou R, Dana T, Bougatsos C, Fu R, Blazina I, Gleitsmann K, et al. Treatments for Localized Prostate Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation. Evidence Synthesis no. 91. AHRQ Publication no. 12-05161-EF-2. (Prepared by the Oregon Evidencebased Practice Center under contract HHSA-290-2007-10057-I-EPC3, Task Order 3.) Rockville, MD: Agency for Healthcare Research and Quality; 2011.
11. Ganz PA, Barry JM, Burke W, Col NF, Corso PS, Dodson E, et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med. 2012;156:591-595. [PMID: 22351514]
12. Wilt TJ. The VA/NCI/AHRQ Cooperative Studies Program #407: Prostate Cancer Intervention Versus Observation Trial (PIVOT): main results from a randomized trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer. Presented at the 107th Annual Meeting of the American Urological Association, Washington, DC, 14-19 May 2011.
13. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al; SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708-17. [PMID: 21542742]
14. Woloshin S, Schwartz LM. The benefits and harms of mammography screening: understanding the trade-offs. JAMA. 2010;303:164-5. [PMID: 20068211]
15. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981-90. [PMID: 22417251]
16. Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst. 2005;97:1132-7. [PMID: 16077071]
17. Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, et al; Scandinavian Prostate Cancer Group Study Number 4. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100:1144-54. [PMID: 18695132]
18. Collin SM, Metcalfe C, Donovan J, Lane JA, Davis M, Neal D, et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int. 2008;102:1400-6. [PMID: 18540932]
19. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-9. [PMID: 19297565]
20. Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brousseau G, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59:311-8. [PMID: 15042607]
21. Sandblom G, Varenhorst E, Rosell J, Löfman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow-up. BMJ. 2011;342:d1539. [PMID: 21454449]
22. Kjellman A, Akre O, Norming U, Törnblom M, Gustafsson O. 15-year followup of a population based prostate cancer screening study. J Urol. 2009;181: 1615-21. [PMID: 19233435]
23. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al; PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125-32. [PMID: 22228146]
24. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148:435-48. [PMID: 18252677]
25. Widmark A. Prospective randomized trial comparing external beam radiotherapy versus watchful waiting in early prostate cancer (T1b-T2, pN0, grade 1-2, M0). Presented at the 53rd Annual Meeting of the American Society for Therapeutic Radiology and Radiation Oncology, Miami, FL, 2-6 October 2011.
26. The ProtecT trial-evaluating the effectiveness of treatment for clinically localised prostate cancer [clinical trial]. Accessed at www.controlled-trials.com /ISRCTN20141297 on 27 April 2012.
27. Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, et al. The Prostate cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009;30: 81-7. [PMID: 18783735]
28. Moore AL, Dimitropoulou P, Lane A, Powell PH, Greenberg DC, Brown CH, et al. Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. BJU Int. 2009;104:1592-8. [PMID: 19549125]
29. Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5_-reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011;365:97-9. [PMID: 21675880]
30. Catalona WJ. Early diagnosis of prostate cancer through PSA testing saves lives. Presented at the 107th Annual Meeting of the American Urological Association, Washington, DC, 14-19 May 2011.
31. Johansson E, Steineck G, Holmberg L, Johansson JE, Nyberg T, Ruutu M, et al; SPCG-4 Investigators. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 2011;12:891-9. [PMID: 21821474]
32. Fransson P, Damber JE, Widmark A. Health-related quality of life 10 years after external beam radiotherapy or watchful waiting in patients with localized prostate cancer. Scand J Urol Nephrol. 2009;43:119-26. [PMID: 18985545]
33. Crawford ED, Grubb R 3rd, Black A, Andriole GL Jr, Chen MH, Izmirlian G, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol. 2011;29:355-61. [PMID: 21041707]
34. Bach PB, Vickers AJ. Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results? [Letter]. J Clin Oncol. 2011;29:e387. [PMID: 21422419]
35. American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Soc; 2011. Accessed at www.cancer.org/acs/groups/content /@epidemiologysurveilance/documents/document/acspc-029771.pdf on 30 April 2012.
36. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993;150:379-85. [PMID: 8326560]
37. Grönberg H. Prostate cancer epidemiology. Lancet. 2003;361:859-64. [PMID: 12642065]
38. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185-91. [PMID: 18678845]
39. Lin K, Croswell JM, Koenig H, Lam C, Maltz A. Prostate-Specific Antigen-Based Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force. Evidence Synthesis no. 90. AHRQ Publication no. 12-05160-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
40. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA. 2005;294:66-70. [PMID: 15998892]
41. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst. 2011;103:462-9. [PMID: 21350221]
42. Wolters T, Roobol MJ, Steyerberg EW, van den Bergh RC, Bangma CH, Hugosson J, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer. 2010;126:2387-93. [PMID: 19739124]
43. Dubben HH. Trials of prostate-cancer screening are not worthwhile. Lancet Oncol. 2009;10:294-8. [PMID: 19261258]
44. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst. 2000;92:613-21. [PMID: 10772678]
45. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Göteborg randomised population-based prostatecancer screening trial. Lancet Oncol. 2010;11:725-32. [PMID: 20598634]
46. Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl. 1995;172:65-72. [PMID: 8578259]
47. Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med. 2009;7:212-22. [PMID: 19433838]
48. McNaughton-Collins M, Fowler FJ Jr, Caubet JF, Bates DW, Lee JM, Hauser A, et al. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. Am J Med. 2004;117:719-25. [PMID: 15541320]
49. Fowler FJ Jr, Barry MJ, Walker-Corkery B, Caubet JF, Bates DW, Lee JM, et al. The impact of a suspicious prostate biopsy on patients' psychological, sociobehavioral, and medical care outcomes. J Gen Intern Med. 2006;21:715-21. [PMID: 16808772]
50. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology. 2002;60:826-30. [PMID: 12429309]
51. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011;186:1830-4. [PMID: 21944136]
52. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010; 102:605-13. [PMID: 20413742]
53. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:868-78. [PMID: 12813170]
54. Hu JC, Gu X, Lipsitz SR, Barry MJ, D'Amico AV, Weinberg AC, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009;302:1557-64. [PMID: 19826025]
55. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300:173-81. [PMID: 18612114]
56. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306: 2359-66. [PMID: 22147380]
57. Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004;171: 2285-90. [PMID: 15126804]
58. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095-101. [PMID: 15870412]
59. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302:1202-9. [PMID: 19755699]
60. Carroll P, Albertsen PC, Greene K, Babaian RJ, Carter HB, Gann PH, et al. Prostate-Specific Antigen Best Practice Statement: 2009 Update. Linthicum, MD: American Urological Assoc; 2009. Accessed at www.auanet.org /content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf on 6 October 2011.
61. American Urological Association. AUA responds to new recommendations on prostate cancer screening [press release]. Linthicum, MD: American Urological Assoc; 7 October 2011.
62. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al; American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70-98. [PMID: 20200110]
63. Lim LS, Sherin K; ACPM Prevention Practice Committee. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. Am J Prev Med. 2008;34:164-70. [PMID: 18201648]